Published in Mental Health Law Weekly, October 30th, 2004
Athena, specialists in diagnostic testing for neurological disorders, plans to make the gene-based Severe Myoclonic Epilepsy of Infancy (SMEI) test available later this calendar year to over 5,000 neurologists for whom it currently performs diagnostic tests.
Until now there has been no genetic test available to clinicians to allow them to distinguish SMEI from less serious forms of epilepsy. Early diagnosis should reduce the cost associated with current diagnostic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.